

# New Dates Announced: ACI's 3rd Annual Summit on Controlled Substances is Returning to Washington DC on July 21-22

*Don't Let the Pandemic Eclipse the Opioid Epidemic*

WASHINGTON, D.C., UNITED STATES, May 4, 2020 /EINPresswire.com/ -- As the world adapts to this new normal, experts are becoming increasingly concerned that the coronavirus pandemic will undermine earnest legislative and enforcement efforts designed to thwart the opioid crisis.

In response, the DEA has published guidance concerning telemedicine, suspicious orders and due diligence, prescriptions, and record and reports, alongside a blitz of other COVID-19-related support.

Don't be left in the dark.

“

It was great to hear from current and former industry leaders and experts from DEA, US AG offices, FDA, etc. Hearing about the current events and upcoming trends and expectations was valuable”

*JM, Kroger Health*

proximately executed.

We look forward to seeing you in-person or virtually this Summer.

[Registration](#) is now open. Please visit us at [www.AmericanConference.com/ControlledSubstances](http://www.AmericanConference.com/ControlledSubstances) for details, or call 888-224-2480 to speak with our customer care team.

American Conference Institute's Global Series of Life Sciences conferences bring together key sector stakeholders from around the globe to explore the most important trends impacting the many industries including pharmaceutical, biotechnology, medical device/diagnostics, and FDA-



3rd Annual Summit on Controlled Substances – Regulation, Litigation, and Enforcement | February 25–26, 2020 | Washington Hilton, Washington, DC

regulated consumer products. Our events cover every facet of legal and business relevance as well as controversy. Visit <https://www.americanconference.com/conferences/life-sciences/> for full list of upcoming events in 2020.

Linda Lam  
American Conference Institute  
+1 212-352-3220  
[email us here](#)  
Visit us on social media:  
[LinkedIn](#)

The brochure is for the 3rd Annual Summit on Controlled Substances, held from July 21-22, 2020, at the Washington Hilton in Washington, DC. The title 'CONTROLLED SUBSTANCES' is prominently displayed in yellow and white, with the subtitle 'REGULATION, LITIGATION, AND ENFORCEMENT' below it. The background features a close-up of various pills. The top left corner includes the ACI logo and the text 'Learn about DEA's COVID-19 response concerning the production of controlled substance medications'. The top right corner has a 'C EARN CLE CREDITS' badge. The middle section lists 'Exclusive Keynotes from DEA, DOJ and FDA on Enforcement Initiatives' with three speakers: Speaker TBA (U.S. Drug Enforcement Administration), Dominic Chiappierino, Ph.D. (U.S. Food and Drug Administration), and Gustav Eyer (U.S. Department of Justice). Below this, it lists 'Associate Sponsors' as ANALYSIS GROUP and NARCX. The right side of the brochure highlights 'Industry thought leaders will help you:' with four key topics: ANALYZE (MDL settlement), ASSESS (cannabinoids), EVALUATE (new medicines), and DEVELOP (compliance program). At the bottom, it lists 'Pre-Conference Workshops' for July 20, 2020, including a bootcamp and a think tank. The footer contains registration information and the ACI logo.

ACI  
American Conference Institute

3<sup>rd</sup> annual summit

July 21-22, 2020 | Washington Hilton, Washington, DC

**CONTROLLED SUBSTANCES**  
REGULATION, LITIGATION, AND ENFORCEMENT

**Exclusive Keynotes from DEA, DOJ and FDA on Enforcement Initiatives:**

- Speaker TBA  
U.S. Drug Enforcement Administration
- Dominic Chiappierino, Ph.D.  
Director, Controlled Substance Staff, Center for Drug Evaluation and Research  
U.S. Food and Drug Administration
- Gustav Eyer  
Director  
Consumer Protection Branch  
U.S. Department of Justice

Associate Sponsors

ANALYSIS GROUP  
ECONOMIC, FINANCIAL, AND STRATEGY CONSULTANTS

NARCX

Industry thought leaders will help you:

- ANALYZE** the implications of the proposed MDL settlement and the probability of a global settlement
- ASSESS** the therapeutic potential of cannabinoids
- EVALUATE** incentives for new medicines to treat pain and addiction
- DEVELOP** a comprehensive controlled substances compliance program

Pre-Conference Workshops | July 20, 2020

- A** Controlled Substances Bootcamp: An Introduction to Key Agencies, Regulation, and Scheduling
- B** Compliance Think Tank: Building and Enhancing an Effective Controlled Substances Compliance Program

> Register Now | Visit us online for updates and new speakers announcements.  
AmericanConference.com/ControlledSubstances | 888.224.2480

a CS Group Company  
Business Information is a Global Content

Download conference brochure here:  
<https://www.americanconference.com/controlled-substances/request-brochure/>

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2020 IPD Group, Inc. All Right Reserved.